Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;52(1):40-43.
doi: 10.1016/j.idnow.2021.12.002. Epub 2021 Dec 15.

Vaccine effectiveness against COVID-19 hospitalization in adults in France: A test negative case control study

Liem Binh Luong Ngyen  1 , Rebecca Bauer  2 , Zineb Lesieur  3 , Florence Galtier  4 , Xavier Duval  5 , Philippe Vanhems  6 , Fabrice Lainé  7 , Pierre Tattevin  8 , Christine Durier  2 , Odile Launay  9 ; FLUVAC Study group
Affiliations

Vaccine effectiveness against COVID-19 hospitalization in adults in France: A test negative case control study

Liem Binh Luong Ngyen et al. Infect Dis Now. 2022 Feb.

Abstract

Background: Measuring vaccine effectiveness (VE) using real-life data is critical to confirm the effectiveness of licensed vaccine, which could strengthen vaccination adherence.

Methods: We measured VE against adult COVID-19 hospitalization in five hospitals in France using a test negative design. We compared the odds of vaccinated patients hospitalized with COVID-19 with the odds of vaccinated patients hospitalized for the same symptoms with a negative test.

Results: A total of 853 patients (463 cases and 390 controls) were included, with a total of 170 patients vaccinated (104 with one dose, 65 with two doses, and one with three doses). There were four cases of breakthrough infections, all in immunocompromised patients. The VE was 84.0% (CI0.95=[72.6; 90.6]) for one dose and 96.2% (CI0.95=[86.8; 98.9]) for two doses.

Conclusion: Our results confirm the high VE of COVID-19 vaccine in France to prevent hospitalizations due to the alpha variant.

Keywords: Alpha variant; COVID-19; France; Vaccine; Vaccine effectiveness.

PubMed Disclaimer

References

    1. Schwarzinger M., Watson V., Arwidson P., Alla F., Luchini S. COVID-19 vaccine hesitancy in a representative working-age population in France: a survey experiment based on vaccine characteristics. Lancet Public Health. 2021;6(4):e210–e221. - PMC - PubMed
    1. Loubet P., Samih-Lenzi N., Galtier F., Vanhems P., Loulergue P., Duval X., et al. Factors associated with poor outcomes among adults hospitalized for influenza in France: a three-year prospective multicenter study. J Clin Virol. 2016;79:68–73. - PubMed
    1. Dagan N., Barda N., Kepten E., Miron O., Perchik S., Katz M.A., et al. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;0(0) [null] - PMC - PubMed
    1. Abu-Raddad L.J., Chemaitelly H., Butt A.A. Effectiveness of the BNT162b2 COVID-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med. 2021;0(0) [null] - PMC - PubMed
    1. Hyams C., Marlow R., Maseko Z., King J., Ward L., Fox K., et al. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. Lancet Infect Dis. 2021 [cited 2021 Jul 27; Available from: https://www.sciencedirect.com/science/article/pii/S1473309921003303] - PMC - PubMed

Substances

Supplementary concepts